Adherence to Guideline-Recommended Cancer Screening in Stroke Survivors: A Nationwide Analysis
- PMID: 35032754
- PMCID: PMC8852296
- DOI: 10.1016/j.jstrokecerebrovasdis.2021.106297
Adherence to Guideline-Recommended Cancer Screening in Stroke Survivors: A Nationwide Analysis
Abstract
Objectives: Cancer can present as stroke. Several cancer types have established screening guidelines. We investigated adherence to guideline-recommended cancer screening in stroke survivors versus the general population.
Materials and methods: We performed a cross-sectional analysis using 2012-2018 data from the CDC's Behavioral Risk Factor Surveillance System (BRFSS) survey. BRFSS is a nationally-representative telephone survey of non-institutionalized Americans that collects data about health conditions and behaviors, including cancer screening. We defined guideline-recommended colorectal, lung, and breast cancer screening based on the U.S. Preventive Services Task Force recommendations. We used survey-specific methods to estimate up-to-date screening rates for those with and without prior stroke. We used logistic regression to estimate the odds of up-to-date screening in stroke survivors compared to those without history of stroke after adjustment for potential confounders.
Results: Among 1,018,440 respondents eligible for colorectal cancer screening, 66% were up-to-date. Among 6,880 respondents eligible for lung cancer screening, 16% were up-to-date. Among 548,434 women eligible for breast cancer screening, 78% were up-to-date. After adjustment for demographics and confounders, stroke survivors were more likely to have up-to-date colorectal cancer screening (OR, 1.10; 95% CI, 1.05-1.16), equally likely to undergo lung cancer screening (OR, 0.99; 95% CI, 0.62-1.59), and less likely to undergo breast cancer screening (OR, 0.87; 95% CI, 0.80-0.94).
Conclusions: In a nationwide analysis, stroke survivors had similar suboptimal adherence to guideline-recommended cancer screening as the general population.
Keywords: Cancer; Malignancy; Neoplasm; Screening; Stroke.
Copyright © 2021 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest Hooman Kamel serves as co-PI for the NIH-funded ARCADIA trial which receives in-kind study drug from the BMS-Pfizer Alliance and in-kind study assays from Roche Diagnostics, serves as Deputy Editor for JAMA Neurology, serves as a steering committee member of Medtronic's Stroke AF trial (uncompensated), and serves on an endpoint adjudication committee for a trial of empagliflozin for Boehringer-Ingelheim. Neal Parikh has received personal fees for medicolegal consulting on stroke. Babak Navi has received personal fees for medicolegal consulting on stroke. The other authors have no disclosures.
References
-
- Navi BB, DeAngelis LM, Segal AZ. Multifocal strokes as the presentation of occult lung cancer. J Neurooncol 2007;85:307–309. - PubMed
-
- Navi BB, Kawaguchi K, Hriljac I, et al. Multifocal stroke from tumor emboli. Arch Neurol2009;66:1174–1175. - PubMed
-
- Virani SS, Alonso A, Benjamin EJ, et al. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation 2020;141:e139–e596. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
